T-3262 IN UROLOGY

DOI

Bibliographic Information

Other Title
  • 泌尿器科領域におけるT-3262の臨床的検討

Abstract

We clinically investigated T-3262, a new antimicrobial agent derived from pyridone-carboxylic acid.<BR>Twenty-five patients with urinary tract infection were treated with T-3262, and the clinical efficacy in 24 patients was evaluated by the criteria of the Japanese UTI Committee. The clinical response in 15 cases of acute uncomplicated cystitis was excellent in 10 cases and moderate in 5 and in both cases of acute uncomplicated pyelonephritis it was excellent. The overall clinical efficacy rate for acute uncomplicated UTI was 100%. The clinical response in 7 patients with chronic complicated cystitis was excellent in 4, the overall efficacy rate being 57.1%. The efficacy was fair in 1 case of chronic complicated pyelonephritis according to the evaluation of the doctor in charge.<BR>Bacteriological response was evaluated in the above 24 cases. Eradication of bacteria was observed in all 17 strains isolated (100%) in uncomplicated UTI and in 6 of 10 strains (60%) in complicated UTI. No adverse reactions were seen.<BR>Our results suggest that T-3262 is useful in treating urinary tract infections.

Journal

  • CHEMOTHERAPY

    CHEMOTHERAPY 36 (Supplement9-Clinical), 935-942, 1988

    Japanese Society of Chemotherapy

Keywords

Details 詳細情報について

Report a problem

Back to top